Atossa Therapeutics updates protocol for breast cancer treatment trial [Yahoo! Finance]
Atossa Therapeutics, Inc. (ATOS)
Last atossa therapeutics, inc. earnings: 11/13 04:10 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.atossagenetics.com
Company Research
Source: Yahoo! Finance
in women with estrogen receptor positive (ER+) / human epidermal growth factor receptor 2 negative (HER2-) breast cancer. The study is assessing the combination regimen as a neoadjuvant treatment in newly diagnosed ER+/HER2- breast cancer patients. The protocol changes involve an increase in the dose of (Z)-endoxifen from 40mg to 80mg once daily, based on safety, efficacy, and pharmacokinetic data from the Phase II EVANGELINE study. The EVANGELINE study is targeting premenopausal women and has shown promising results with a significant reduction in the cellular proliferation marker Ki-67 and tumour size. Data from the initial 40mg cohort of the EVANGELINE study indicated a 92% average reduction in Ki-67 and a 37% average decrease in target lesion size after a 24-week treatment period. The trial has now progressed to an 80mg cohort, aiming to optimise drug concentrations for enhanced antitumor efficacy. In addition to the dose increase, the combination trial will now includ
Show less
Read more
Impact Snapshot
Event Time:
ATOS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ATOS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ATOS alerts
High impacting Atossa Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
ATOS
News
- Atossa Therapeutics Appoints Heather Rees as Chief Financial Officer [Yahoo! Finance]Yahoo! Finance
- Atossa Therapeutics Appoints Heather Rees as Chief Financial OfficerGlobeNewswire
- Atossa Therapeutics, Inc. (NASDAQ: ATOS) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $6.00 price target on the stock.MarketBeat
- Atossa Therapeutics Announces Updated Protocol for Clinical Trial Evaluating (Z)-Endoxifen in Combination with Abemaciclib (VERZENIO®) in Women with ER+/HER2- Breast CancerGlobeNewswire
- Atossa Therapeutics, Inc. (NASDAQ: ATOS) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald.MarketBeat
ATOS
Sec Filings
- 7/2/24 - Form 8-K
- 7/1/24 - Form 4
- 7/1/24 - Form 4
- ATOS's page on the SEC website